New study reveals how blood cancers outsmart BTK-targeted therapies

Дата публикации: 28-07-2026 17:40:06

Scientists at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, and collaborators have uncovered a rare genetic mutation that enables some blood cancers to evade both approved Bruton tyrosine kinase (BTK) inhibitors and newer BTK degraders, a finding that could help shape the next generation of therapies for patients with chronic lymphocytic leukemia (CLL) and related malignancies.

Основное содержимое страницы с новостью.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Reshaping the gut microbiome can boost chemotherapy delivery to tumors	0	6.61	01-08-2026
2	Scientists discover why some cancers survive chemotherapy	0	7.21	17-05-2026
3	Team finds way to reverse ovarian cancer’s chemo resistance	5	8	25-06-2026
4	Новое лекарство от агрессивных видов рака крови создают в Петербурге	6	7	17-07-2026
5	Malaga searches for 'switch' that halts most aggressive phase of blood cancer	0	10	13-05-2026
6	Chemotherapy leaves detectable DNA fingerprints in childhood tumors within 18 months	0	8.21	23-07-2026
7	A hidden weakness in deadly cancers could lead to powerful new treatments	0	7.28	04-07-2026
8	Common blood pressure drug could make cancer therapy far more powerful	0	9.71	11-07-2026
9	New, improved method to find and isolate the strongest cancer-fighting immune cells	7	8	08-07-2026
10	Cancer-specific c-Myc mapping reveals overlooked SLK protein as treatment target	0	17.95	13-08-2026

Классификация: Наука. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 8.1. Источник: medicalxpress.com.